Literature DB >> 12393099

MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells.

Martina Werle1, Ulrike Schmal, Katharina Hanna, Jörg Kreuzer.   

Abstract

Activation of vascular endothelial cells (ECs) plays an important pathogenic role in the development of atherosclerosis. Monocyte chemoattractant protein-1 (MCP-1) is a potent chemoattractant of monocytes. Besides induction of monocyte recruitment, it has been suggested that MCP-1 can also affect the cellular responses of ECs. We investigated whether MCP-1 activated the three major mitogen activated protein (MAP)-kinases extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) and p38 MAPK. Stimulation of ECs with MCP-1 induced a time- and concentration-dependent activation of all three MAP-kinases, concentrations as low as 0.1 ng/ml were sufficient for this mechanism. MCP-1 also induced secretion of matrix metalloproteinase (MMP)-2 which along with ERK activation was inhibited by PD098059. The results demonstrate that MCP-1 can lead to direct activation of MAP kinases together with induction of MMP2 in ECs. Our data thus propose a new mechanism for the proatherogenic effect of MCP-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393099     DOI: 10.1016/s0008-6363(02)00600-4

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  28 in total

1.  Induction of autoimmunity to brain antigens by developmental mercury exposure.

Authors:  Yubin Zhang; Donghong Gao; Valerie J Bolivar; David A Lawrence
Journal:  Toxicol Sci       Date:  2010-11-11       Impact factor: 4.849

2.  The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells.

Authors:  Jungsook Cho; Donna L Gruol
Journal:  J Neuroimmunol       Date:  2008-06-27       Impact factor: 3.478

Review 3.  Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.

Authors:  Harris A Gelbard; Stephen Dewhurst; Sanjay B Maggirwar; Michelle Kiebala; Oksana Polesskaya; Howard E Gendelman
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

4.  Phosphoproteomic characterization of the signaling network resulting from activation of the chemokine receptor CCR2.

Authors:  Cheng Huang; Simon R Foster; Anup D Shah; Oded Kleifeld; Meritxell Canals; Ralf B Schittenhelm; Martin J Stone
Journal:  J Biol Chem       Date:  2020-04-02       Impact factor: 5.157

5.  CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension.

Authors:  Yen-Rei A Yu; Lan Mao; Claude A Piantadosi; Michael D Gunn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

6.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.

Authors:  Evis Harja; De-xiu Bu; Barry I Hudson; Jong Sun Chang; Xiaoping Shen; Kellie Hallam; Anastasia Z Kalea; Yan Lu; Rosa H Rosario; Sai Oruganti; Zana Nikolla; Dmitri Belov; Evanthia Lalla; Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice.

Authors:  Y Nio; T Yamauchi; M Iwabu; M Okada-Iwabu; M Funata; M Yamaguchi; K Ueki; T Kadowaki
Journal:  Diabetologia       Date:  2012-09-16       Impact factor: 10.122

8.  Burn injury reveals altered phenotype in mannan-binding lectin-deficient mice.

Authors:  Mette Møller-Kristensen; Michael R Hamblin; Steffen Thiel; Jens Chr Jensenius; Kazue Takahashi
Journal:  J Invest Dermatol       Date:  2007-03-15       Impact factor: 8.551

9.  Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines.

Authors:  J Mark Brown; Maria Sandberg Boysen; Soonkyu Chung; Olowatoyin Fabiyi; Ron F Morrison; Susanne Mandrup; Michael K McIntosh
Journal:  J Biol Chem       Date:  2004-04-02       Impact factor: 5.157

10.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.